Compare BeiGene Ltd. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 17.83% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -83.25
2
The company has declared negative results in Dec'2023 after 4 consecutive positive quarters
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
HKD 263,164 Million ()
122.00
NA
0.00%
-0.70
11.46%
7.05
Revenue and Profits:
Net Sales:
11,825 Million
(Quarterly Results - Mar 2026)
Net Profit:
1,776 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.95%
0%
-13.95%
6 Months
-10.44%
0%
-10.44%
1 Year
28.12%
0%
28.12%
2 Years
79.65%
0%
79.65%
3 Years
29.84%
0%
29.84%
4 Years
116.3%
0%
116.3%
5 Years
-10.35%
0%
-10.35%
BeiGene Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
77.04%
EBIT Growth (5y)
17.83%
EBIT to Interest (avg)
-83.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.45
Sales to Capital Employed (avg)
0.27
Tax Ratio
45.95%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
122
Industry P/E
Price to Book Value
9.04
EV to EBIT
82.06
EV to EBITDA
62.32
EV to Capital Employed
21.38
EV to Sales
6.87
PEG Ratio
0.87
Dividend Yield
NA
ROCE (Latest)
26.06%
ROE (Latest)
7.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
11,825.30
11,652.30
1.48%
Operating Profit (PBDIT) excl Other Income
2,274.10
1,719.00
32.29%
Interest
257.00
160.00
60.62%
Exceptional Items
0.40
-309.90
100.13%
Consolidate Net Profit
1,776.50
517.20
243.48%
Operating Profit Margin (Excl OI)
165.10%
123.50%
4.16%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 1.48% vs 5.49% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 243.48% vs -47.03% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
41,654.50
29,731.20
40.10%
Operating Profit (PBDIT) excl Other Income
4,590.50
-3,093.40
248.40%
Interest
454.00
365.90
24.08%
Exceptional Items
-580.90
-149.60
-288.30%
Consolidate Net Profit
2,236.90
-5,031.20
144.46%
Operating Profit Margin (Excl OI)
83.70%
-149.10%
23.28%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 40.10% vs 54.45% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 144.46% vs 27.11% in Dec 2024
About BeiGene Ltd. 
BeiGene Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






